ERBB2 and breast carcinoma: Lapatanib is another tyrosine kinase inhibitor used in treatment of HER2+ breast cancer, which when used in combination with capecitabine was found to increase progression-free survival to 8.4 months compared to 4.4 months receiving capecitabine monotherapy at the primary endpoint of a clinical trial of metastatic breast cancer patients (44).